

## Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4, or 6 C-EDGE: Treatment Experienced


# Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4, or 6

## C-EDGE TE: Features

- **Study Design:** Randomized, open label, parallel-group, phase 3 trial examining the safety and efficacy of a fixed-dose combination of elbasvir-grazoprevir with or without ribavirin for 12 or 16 weeks in treatment-experienced adults with GT 1, 4, or 6 HCV and previous failure of peginterferon plus ribavirin
- **Entry Criteria:**
  - 18 years or older
  - Chronic HCV Genotype 1, 4 or 6
  - HCV RNA  $\geq 10,000$  IU/mL
  - History of peginterferon plus ribavirin treatment failure
  - Patients with compensated cirrhosis accepted
  - Some patients with HIV infection accepted
- **Primary End-Point:** SVR12

# Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4, or 6

## C-EDGE TE: Design



**Abbreviations:** EBR-GZR = elbasvir-grazoprevir; RBV = ribavirin

### Drug Dosing

Elbasvir-grazoprevir (50/100 mg): fixed dose combination; one pill once daily

Ribavirin (weight-based and divided bid): 800 to 1400 mg/day

# Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4, or 6

## C-EDGE TE: Baseline Characteristics


Baseline Characteristic	12-Week Treatment		16-Week Treatment	
	EBR-GZR (n = 105)	EBR-GZR + RBV (n = 104)	EBR-GZR (n = 105)	EBR-GZR + RBV (n = 106)
Age, yrs median (range)	56 (25–76)	56 (23–75)	55 (31–73)	55 (19–77)
Male sex, %	63	69	66	60
Race, n (%)				
Caucasian	66 (63)	70 (67)	72 (69)	78 (74)
African American	23 (22)	24 (23)	9 (9)	15 (14)
Asian	15 (14)	9 (9)	22 (21)	10 (9)
HCV Genotype, 1a%	61 (58)	60 (58)	48 (46)	58 (55)
HCV Genotype, 1b	34 (32)	29 (28)	48 (46)	36 (34)
HCV Genotype, 4	9 (9)	15 (14)	5 (5)	8 (8)
HCV Genotype, 6	0 (0)	0 (0)	4 (4)	2 (2)
Cirrhosis, %	37 (35)	35 (34)	38 (36)	37 (35)
HIV coinfection, %	6 (6)	5 (5)	6 (6)	4 (4)
Prior Treatment Relapse, %	35 (33)	38 (37)	38 (36)	40 (38)
Partial Treatment response, %	21 (20)	22 (21)	21 (20)	23 (22)
Prior null Treatment Response, %	49 (47)	44 (42)	46 (44)	43 (41)

Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.

# Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4, or 6

## C-EDGE TE: Results

C-EDGE TE: SVR 12 with Elbasvir-Grazoprevir\*, by Genotype




\* Analysis per protocol: excluding patients who dropped out due to reasons other than virologic failure

# Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4, or 6

## C-EDGE TE: Results

C-EDGE TE: SVR 12\* by Regimen and Treatment Duration (GT 1, 4, or 6)




\* Analysis per intent to treat

# Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4, or 6

## C-EDGE TE: Results


C-EDGE TE: SVR 12 by Regimen, Treatment Duration, and GT1 Subtype



# Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4, or 6

## C-EDGE TE: Results

C-EDGE TE: SVR 12 in Patients with Baseline NS5A RAVs\*



\*NS5A is by population-based sequencing (25% sensitivity threshold)\*

Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.

# Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4, or 6 C-EDGE TE: Results

**Conclusions:** “The combination tablet of elbasvir and grazoprevir, with or without ribavirin, was highly efficacious in inducing an SVR12 in patients with HCV genotype 1, 4, or 6 infection failed by previous treatment with peg-interferon and ribavirin, including patients with cirrhosis and/or a prior null response. The treatment was generally well tolerated.”

# Acknowledgments

**Hepatitis C Online** is funded by a cooperative agreement from the Centers for Disease Control and Prevention (CDC-RFA- PS21-2105). This project is led by the University of Washington Infectious Diseases Education and Assessment (IDEA) Program.



*The content in this presentation is that of the author(s) and does not necessarily represent the official position or views of, nor an endorsement, by the Centers for Disease Control and Prevention.*